2023 Annual Meeting | Industry Therapeutic Update from Novo Nordisk: Novel Approaches and Targets in AD and PD

Date Monday 04/24/23

Time 06:00 PM - 09:00 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Jeffrey L. Cummings, MD, FAAN, Rhoda Au, PhD, Roger Barker, PhD, Sharon Cohen, MD, Rachel Dolhun, MD, Harini Sarva, MD, FAAN, Harris Eyre, Malu Gamez Tansey

Topic(s) General Neurology, Aging and Dementia, Aging, Dementia, and Behavioral Neurology, Movement Disorders

Learning Objectives An interactive, discussion-based session that will aim to advance our understanding of Alzheimer's and Parkinson's disease pathology and patient-centered care.
The program will focus on upcoming treatment targets, opportunities in digital health technologies as well as clinical applications and other nonmedicinal aspects of Alzheimer's and Parkinson's disease management. We will further identify how brain health strategies can improve the lives of people living with neurodegenerative diseases.
Chair:
Jeffrey Cummings, M.D., Sc.D.
Speakers:
Rhoda Au, Ph.D.
Roger Barker, BA, MBBS, MRCP, PhD
Sharon Cohen, MD, FRCPC
Rachel Dolhun, M.D., DipABLM
Harris Eyre, M.D., Ph.D.
Malu Gamez Pansey Ph.D.
Harini Sarva. M.D.
Please note that no CME will be given by any accredited organization for attending. Additionally, Industry Therapeutic Program Content and the views expressed herein are those of the presenting corporate entity and not those of the AAN. These programs are not an part of the 2023 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research, use of pre-FDA drugs, or other research information that may be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Event Timeline
06:00 PM - 09:00 PM EST	Speaker	Industry Therapeutic Update from Novo Nordisk: Novel Approaches and Targets in AD and PD

Faculty Disclosures
Jeffrey L. Cummings, MD, FAAN	Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Actinogen, Acumen, AlphaCognition, ALZpath, Aprinoia, AriBio, Artery, Biogen, Biohaven, BioVie, BioXcel, Bristol-Myers Squib, Cassava, Cerecin, Diadem, Eisai, GAP Foundation, GemVax, Janssen, Jocasta, Karuna, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, NervGen, New Amsterdam, Novo Nordisk, Oligomerix, ONO, Optoceutics, Otsuka, Oxford Brain Diagnostics, Prothena, ReMYND, Roche, Sage Therapeutics, Signant Health, Simcere, sinaptica, Suven, TrueBinding, Vaxxinity, and Wren pharmaceutical, assessment, and investment companies. Dr. Cummings has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia, Biogen, Genentech, Grifols, Janssen, Karuna, Otsuka, reMYND, Roche, Signant Health. Dr. Cummings has stock in Artery, Vaxxinity, Behrens, Alzheon, MedAvante-Prophase, and Acumen. Dr. Cummings has received research support from NIH. Dr. Cummings has received research support from NIGMS. Dr. Cummings has received intellectual property interests from a discovery or technology relating to health care.
Rhoda Au, PhD	Dr. Au has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NovoNordisk. Dr. Au has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GSK. Dr. Au has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Au has received publishing royalties from a publication relating to health care. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with Davos Alzheimer's Collaborative. Dr. Au has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with High Lantern.
Roger Barker, PhD	Roger Barker, PhD has nothing to disclose.
Sharon Cohen, MD	Dr. Cohen has nothing to disclose.
Rachel Dolhun, MD	Dr. Dolhun has received personal compensation for serving as an employee of The Michael J. Fox Foundation.
Harini Sarva, MD, FAAN	The institution of Dr. Sarva has received research support from Insightec. The institution of Dr. Sarva has received research support from NeuroNext. The institution of Dr. Sarva has received research support from Neuroderm. The institution of Dr. Sarva has received research support from Sun Pharma. The institution of Dr. Sarva has received research support from Prevail. The institution of Dr. Sarva has received research support from Bluerock Therapeutics. The institution of Dr. Sarva has received research support from Biogen. The institution of Dr. Sarva has received research support from Roche. The institution of Dr. Sarva has received research support from National Institute of Aging. The institution of Dr. Sarva has received research support from Michael J Fox Foundation. The institution of Dr. Sarva has received research support from Novo Nordisk. The institution of Dr. Sarva has received research support from Bukwang. The institution of Dr. Sarva has received research support from Bial. The institution of Dr. Sarva has received research support from Cerevance. The institution of Dr. Sarva has received research support from UCB. The institution of Dr. Sarva has received research support from MeiraGTX.
Harris Eyre	No disclosure on file
Malu Gamez Tansey	No disclosure on file

��ɫ��

��ɫ��